GSK's $1B Indian tender offer to open; Aegerion nabs Canadian OK for Juxtapid; Wockhardt profits plummet on FDA move;

@FiercePharma: Feds put Teva's Copaxone, Azilect marketing under FCA microscope. Story | Follow @FiercePharma

@TracyStaton: Best-read story this AM in FiercePharma: FDA panel could give Bayer painkiller an edge over Pfizer. More | Follow @TracyStaton

@EricPFierce: The engagement is off for CFR and Adcock Ingram. Is a spurned suitor in the wings? News | Follow @EricPFierce

@GalenMoore: Painkillers: A heart-risk warning in place since Vioxx could get lifted--for just one drug. Story | Follow @GalenMoore

> GlaxoSmithKline's ($GSK) $1 billion tender offer for an increased stake in its Indian unit will open Feb. 18 and remain so through March 5. Report

> Aegerion Pharmaceuticals' ($AEGR) blood-lipid drug Juxtapid won regulatory approval in Canada. Release

> Indian generics maker Wockhardt saw its fiscal third-quarter profits drop by 29% after the U.S. FDA took action against one of its plants. Report

> SkyePharma is up for a 3 million euro ($4.1 million) milestone payment now that its respiratory drug Flutiform is approved in France. Report

> The Chinese drugmaker Shanghai Fudan Forward won regulatory approval for a private placement of stock. Report

> Zanzibar's president, Ali Mohamed Shein, invited Indian drugmakers to invest in his country. Report

Medical Device News

@FierceMedDev: Hackers broke into the Big 3--and left the door open for months, report says. Story | Follow @FierceMedDev

@MarkHFierce: Yes, med tech industry, you should watch India's regulatory reform process, but regulators aren't exactly rushing. Item | Follow @MarkHFierce

@MichaelGFierce: ICYMI: Check out our special report: The top drug delivery partnerships of 2013. Report from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Researchers at Harvard and MIT develop innovative hearing aid chip. More | Follow @EmilyWFierce

> WSJ: Device VC funding drops to 8-year lows, but seeds are in place for a rebound. Story

> Roche + Cancer Genetics will expand cancer molecular Dx testing into warmer waters. Article

> Medtronic faces another pretrial setback over its Infuse bone growth implant. News

Biotech News

@FierceBiotech: Can Sanofi's partnership with Regeneron redeem the French biotech's R&D reputation? Read | Follow @FierceBiotech

@JohnCFierce: J&J team marks another setback on depression as mid-stage study flops. Story | Follow @JohnCFierce

@DamianFierce: Merck takes aim at Sanofi with a Lantus biosimilar of its own. More | Follow @DamianFierce

@EmilyMFierce: Gates Foundation delivers an $11.8M grant to fuel tuberculosis R&D. News | Follow @EmilyMFierce

> FDA reviewers paint radically contrasting pictures of The Medicines Co.'s cangrelor. Piece

> Antibiotics developer Melinta lands a $70M round for PhIII development blitz. Story

CRO News

> Covance's sales soar on a jump in late-stage testing. News

> AstraZeneca spares its WuXi-partnered drug in an R&D slash and burn. Story

> BioOutsource doubles its capacity in a bet on the biosimilars boom. Article

> Wellcome bets $4M on CRO Selcia's university team-up. News

> BioClinica plots an EU expansion in the midst of its latest merger. Article

> Report: CRO biz set for another boom. Item

Biotech IT News

> Report: Boston Scientific, Medtronic and St. Jude's networks hacked last year. Story

> Big Pharma players team with NIH to build a diabetes genomics database. Article

> The FDA is making adverse event and recall data available to app developers. Story

> U.K.'s medical research council commits $52M to medical record bioinformatics. News

> The FDA will break up its electronic submission guidance into a series of documents. Article

> Oracle is bringing Siri-like speech recognition to clinical trials. Item

And Finally... Jazz Pharmaceuticals ($JAZZ) broke ground on its new R&D and manufacturing facility in Ireland. Report

Suggested Articles

Pfizer will exit its Perth, Australia sterile injectables manufacturing site by 2024 as part of a global production reorganization effort.

Agios has withdrawn a European application for Tibsovo in AML after the same phase 1 data that earned it an FDA nod failed to impress the EMA.

Sanofi is reportedly considering a sale of some of its anti-inflammation drugs that could snare $234 million as the company pivots toward Dupixent.